Infections due to Candida spp. are increasing in incidence as the numb
er of immune compromised patients increases. The common presentation o
f Candida mucositis and oral infections includes atrophic candidiasis,
angular cheilitis, leukoplakia and oesophagitis. An increasing spectr
um of antifungal agents, including imidazoles, are available for treat
ment and suppression of this common infection. In chronically immune-c
ompromised patients such as those with severe HIV related immune defic
iency, eradication of the infection may not be possible. This requires
a stepwise approach to management and may require the use of potent,
toxic agents such as amphotericin B to suppress the symptoms and signs
of infection sufficiently to provide the patient with symptomatic rel
ief. Resistant organisms are also becoming a greater problem in this p
atient population.